Association of retinal nerve fiber abnormalities with serum CNTF and cognitive functions in schizophrenia patients

Yanhong Liu1*, Lvzhen Huang2*, Yongsheng Tong1, Jingxu Chen1, Dongfang Gao1 and Fude Yang1

1 Peking University Huilongguan Clinical Medical School, Beijing Huilongguan Hospital, Peking University, Beijing, China
2 People’s Hospital of Peking University, Peking University, Beijing, China
*These authors contributed equally to this work.

ABSTRACT

Background. Recent studies have reported reductions in retinal nerve fiber layers (RNFL) in schizophrenia. Ciliary neurotrophic factor (CNTF) has shown protective effects on both the neurogenesis and retina. This study aimed at investigating retinal abnormalities and establishing their correlation with serum CNTF and cognitive impairments in schizophrenic Chinese patients.

Methods. In total, 221 patients diagnosed with schizophrenia and 149 healthy controls were enrolled. Serum CNTF and clinical features of patients were investigated. Cognitive functions were evaluated with Repeatable Battery for the Assessment of Neuropsychology Status (RBANS). RNFL thickness and macular thickness (MT) of both eyes were measured with optical coherence tomography (OCT). T-tests and analysis of covariance were used to compare the variables between the patient and control groups, while multiple linear regression analysis was performed to determine the associations of RNFL thickness, CNTF and cognitive impairments.

Results. RNFL was found thinner in patients than in healthy controls (right: 88.18 ± 25.84 µm vs. 102.13 ± 14.32 µm, p = 0.001; left: 92.84 ± 13.54 µm vs. 103.71 ± 11.94 µm, p < 0.001). CNTF was lower in the schizophrenia group (1755.45 ± 375.73 pg/ml vs. 1909.99 ± 368.08 pg/ml, p = 0.001). Decline in RNFL thickness was found correlated with course of illness and serum CNTF in patients (all p < 0.05). Similarly, cognitive functions such as immediate memory and visuospatial functions were also found correlated with decline in RNFL thickness.

Conclusion. Decline in RNFL thickness was associated with cognitive impairments of schizophrenia and CNTF serum concentration. The possibility of reduction in RNFL thickness as a biomarker for schizophrenia needs to be further examined.

Subjects Neuroscience, Cognitive Disorders, Neurology, Psychiatry and Psychology
Keywords Schizophrenia, Retinal nerve fiber, CNTF

How to cite this article Liu Y, Huang L, Tong Y, Chen J, Gao D, Yang F. 2020. Association of retinal nerve fiber abnormalities with serum CNTF and cognitive functions in schizophrenia patients. PeerJ 8:e9279 http://doi.org/10.7717/peerj.9279
INTRODUCTION

Schizophrenia has been recognized as an abnormal development of brain networks. Involvement of neurodevelopmental mechanisms in the etiology of schizophrenia has been supported by various magnetic resonance imaging (MRI) and electrophysiological studies (Lavoie, Maziade & Hébert, 2014; Di et al., 2019; Zhang et al., 2019). The apoptosis or blocked development of neurons can be manifested as thinning of gray matter, enlargement of ventricles and the deepening of sulci in childhood-to-adolescence-onset schizophrenia (Gao et al., 2019).

Retina emerges from the diencephalon and gradually differentiates into the neural components of the eyes (Chu et al., 2012). Eyes transmit images of the outside world to the brain via parallel processing (Wässle, 2004). Effects of structural and functional changes in the brains of schizophrenia patients can also reflect in the retina. Therefore, the retina, as part of the whole nervous system and an easily accessible substrate for investigating brain pathology (Adams & Nasrallah, 2018), may potentially be associated with the complex etiology of schizophrenia (Schönfeldt-Lecuona et al., 2020). Observation of the retinal nerve structure and exploration of its correlation with cognitive impairments may contribute to a better understanding of the pathogenesis of schizophrenia.

Optical coherence tomography (OCT) is a fast and noninvasive imaging technology for displaying the retinal structure with an axial resolution of 5 μm or less (Hu, You & Zhang, 2015). Previous research using OCT has shown abnormal retinal structure (Silverstein & Rosen, 2015), including atrophy of the macula and the retina nerve fiber layers (RNFL), in patients with Alzheimer’s Disease (AD) (Moschos et al., 2012) and other neurological diseases related to cognitive impairments such as Parkinson’s disease and multiple sclerosis (Satue et al., 2014; Behbehani et al., 2015).

Cognitive impairments in schizophrenia, such as damage to working memory, have been related to the dysfunction of hippocampus (Grimm et al., 2018; Bygrave et al., 2019). On the other hand, previous studies have identified the promoting effect of ciliary neurotrophic factor (CNTF) on the repair of hippocampal neurons (Semkova, Häberlein & Krieglstein, 1999; Liu et al., 2003). Since serum nerve growth factor has protective effects on regional gray matter atrophy in schizophrenia (Neugebauer et al., 2019), thus it is reasonable to postulate that CNTF is one the factors for neuron nutrition that may in turn prevent impairments in RNFL and cognition.

However, associations among CNTF, RNFL and cognitive impairments in schizophrenia are not yet clear. Furthermore, association of RNFL abnormalities with the progression of schizophrenia also needs to be investigated scientifically. On the basis of neurodevelopmental hypothesis, CNTF can be a potential protective factor of schizophrenia (Lavedan et al., 2008); however, it needs to be further investigated. This study was designed to investigate retinal structural abnormalities and their correlations with CNTF and cognitive function in Chinese inpatients with schizophrenia. It was hypothesized that schizophrenia patients may show reduced RNFL thickness and that attenuated thickness may possibly be linked to lower levels of CNTF and cognitive impairments in schizophrenia.
MATERIALS AND METHODS

Recruitment of subjects
Inpatients with schizophrenia and normal controls in 18–65 years age range were consecutively enrolled in Beijing Huilongguan Hospital from July 2018 to May 2019. Written informed consent was provided by participants or their guardians. Schizophrenia was diagnosed in patients according to the Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 4th version (DSM-IV, American Psychiatric Association, APA). Normal controls were voluntarily recruited from hospital staff and nearby communities. Normal controls had no current or previous psychiatric history according to the structured clinical interview for DSM-IV (SCID-I). Proper informed consents were obtained all subjects or their guardians. The study was approved by Institutional Review Board of Beijing Huilongguan Hospital (number 2018-33).

Exclusion criteria
Subjects with acute and chronic medical conditions, including inflammation, pregnancy, hypertension, head trauma, diabetes mellitus, drug and alcohol abuse or addiction, glaucoma, cataracts, high astigmatism (sphere diopter >4 and cylinder diopter >2), and optic media opacities were excluded from both the groups.

Screening for current clinical features
Subjects in both groups were screened for their mean arterial pressure (MAP) and body mass index (BMI). Similarly, current three months smoking habits of all the subjects were recorded in order to consider smoking habit effect on retina. Positive family history of schizophrenia was recorded for the subject in patients' group. Daily doses of antipsychotics taken by each patient were collected according to the medical records and were then converted to the olanzapine equivalent dose (OED) (Jonas et al., 2014; Meier et al., 2015).

Measurement of serum CNTF
Blood samples from both the groups were collected at 6.30 a.m. after an overnight fast. Blood was allowed to coagulate at room temperature for 10–20 min followed by centrifugation at 300 RPM for 10 min. Serum was separated immediately stored at −80 °C till further analysis. Serum CNTF was measured with 96-well ELISA kits (Abcam, USA) following the manufacturer’s instructions (Nunes et al., 2018). To prevent the effects of metabolism on the optic nerve and vessels, levels of relevant variables such serum glucose, cholesterol, uric acid and alanine aminotransferase were measured and statistically controlled (Shiba et al., 2017). All the tests were performed in duplicate by certified technician blinded to the study.

Measurement of cognitive functions
Cognitive impairments were measured in terms of Attention, Language, Visuospatial/Constructional, Immediate Memory, Delayed Memory and Total Scale using Repeatable Battery for the Assessment of Neuropsychology Status (RBANS). RBANS is a brief battery assessment for cognitive functioning originally used in dementia (Randolph et al., 1998). It comprises 12 subscales that contribute to six indices: Attention, Language,
Visuospatial/Constructional, Immediate Memory, Delayed Memory and Total Scale. It is now commonly used in the assessment of cognitive impairment of schizophrenia (Man et al., 2018; Wang et al., 2019).

**Ophthalmic examination and measurement of RNFL and MT**

All patients and normal controls were subjected to comprehensive ophthalmic examination by ophthalmologists. Best corrected visual acuity of both the eyes was measured through Snellen visual acuity. Anterior slit lamp microscopy, Goldman tonometer, and 90D focusing lens were used to exclude eye diseases and measure intraocular pressure. All the subjects underwent scan for measuring RNFL and Macular thickness (MT). For this purpose, Spectral domain OCT (Topcon 2002 type, Japan) scan was performed by ophthalmologist for both eyes of subjects. Clear images of the retina were captured with autofocused OCT camera (axial resolution 5 µm; lateral resolution 10 µm). For RNFL, 3D data were obtained with an OCT raster centered on the optic nerve head in the “6 mm × 6 mm” cube with a 512 × 218 scan and 200 pixels. OCT software (version 8.42) automatically focused on the center of the disc and then extracted a circle with a diameter of 3-4 mm around the papilla to measure the RNFL thickness. RNFL thickness was measured at the 12 clock positions and in the four 90° quadrants of the whole eyeball, including the superior, inferior, nasal and temporal quadrants. The macular region was scanned in a radial “6 mm × 6 mm” region at 1024 × 12 and 200 superpixels. According to the grid definition by the Early Treatment Diabetic Retinopathy Study (ETDRS), a central circle (the foveal region), an inner ring and an outer ring were each divided into four quadrants with the OCT centered automatically on the fovea (Ascaso et al., 2015). MT was measured from the inner limiting membrane (ILM) to the retinal pigment epithelium (RPE). Total and average MT and RNFL thickness (microns) were all automatically calculated. Additionally, the disc area and cup volume were directly output from OCT.

**Statistical analysis**

SPSS 20.0 software was used for analysis of data. The Kolmogorov–Smirnov test was used to confirm whether the data followed a normal distribution. Comparisons of demographic variables between patient and control groups were performed with independent sample t-tests and the chi-square test. Analysis of covariance was used to compare the thickness of RNFL and MT between patients and controls, adjusted for age, sex, OED and smoking. Multiple linear regression analysis was used to assess the thickness of RNFL and MT with the effects of illness duration and CNTF in the patients after controlling for age, sex, MAP, OED, smoking habits, positive family history, uric acid, glucose, and cholesterol levels. RNFL or MT was analyzed as a dependent variable. Illness duration, CNTF and all above controlled variables were analyzed as independent variables. Then, backward stepwise analysis was performed. Multiple linear regression analysis was also used to assess the cognitive function with the effects CNTF and RNFL in the patients after controlling for age, sex, smoking and duration of illness. The indices of RBANS were analyzed as dependent variables, and CNTF and RNFL were analyzed as independent variables. A \( p < 0.05 \) was considered statistically significant.
RESULTS

A total of 221 patients with schizophrenia and 149 healthy controls were enrolled in this study. Demographic characteristics of the enrolled subjects are summarized in Table 1. There were significant differences in age (44.20 ± 12.02 vs. 41.59 ± 9.37 y, p = 0.004), sex and smoking habits between patients and controls (p ≤ 0.001). Clinical features such as MAP and BMI of subjects both in schizophrenia patients and control groups did not show any significant difference as shown in Table 1. The levels of serum uric acid and cholesterol were significantly higher in schizophrenia patients group (p = 0.012, p < 0.001), while level of serum glucose was lower in schizophrenia patients as compared to subjects in control group (p = 0.015). Results further showed that serum CNTF level was significantly lower in schizophrenia patients as compared to subjects in control group (1755.45 ± 375.73 vs. 1709.99 ± 368.08 pg/ml, t = −3.347, p = 0.001).

Retinal abnormalities were measured in terms of changes in MT and RNFL thickness and were investigated for their correlation with schizophrenia. As shown in Table 2, the RNFL thickness of both eyes in schizophrenia patients was found decreased when compared with that of normal controls (p < 0.001), however, the disc area and cup volume of both eyes’ retinas were not significantly different between the schizophrenia patients and subjects in control group. Although the average MT was not significantly different between the two groups, the MTs in the inner and outer rings of both eyes were slightly thinner in the patients group as compared to normal controls (p < 0.05). Results also revealed significant reduction in macula thickness of schizophrenia patients at the central region of the right macula and temporal quadrant of the left macula (p < 0.05).

Changes in MT and RNFL thickness were also investigated for their correlation with serum CNTF and duration of illness. Results revealed that MT was not significantly correlated with serum CNTF and duration of illness in patients with schizophrenia (p > 0.05). On other hand, changes in RNFL thickness revealed significant correlation with serum CNFT as well as duration of illness as shown in Table 3. Total thickness of RNFL of both eyes significantly decreased along with decline in serum CNTF and prolonged course of schizophrenia. To further authenticate the correlation of retinal abnormalities with schizophrenia, effects of changes in RNFL thickness on cognitive functions were investigated. The scores of immediate memory and visuospatial/constructional index apparently decreased with decline in RNFL thickness (p1 = 0.033; p2 = 0.008). Similarly, the score of language index slightly decreased with decline both in serum CNTF and RNFL thickness. Effects of serum CNFT on all other cognitive functions are shown in Table 4.

DISCUSSION

This study aimed at investigating the association of retinal abnormalities with serum CNTF level and other cognitive impairments in schizophrenia patients. Retinal abnormalities were measured in terms of changes in MT and RNFL thickness. Results of the current study revealed an uneven atrophy of MT and RNFL in schizophrenia patients. Moreover, a total thickness of RNFL in both the eyes of schizophrenia patients was found significantly correlated with decline in serum CNTF concentration. When further investigated in terms
Table 1  Participant demographics and differences in cognitive function between schizophrenia and normal groups.

| Mean ± SD                                      | Schizophrenia group | Control group | t/χ²   | p     |
|------------------------------------------------|---------------------|---------------|--------|-------|
| Age, y                                         | 44.20 ± 12.02       | 41.59 ± 9.37  | 2.964  | 0.004 |
| Sex Female, n                                  | 98                  | 54            | 24.49  | 0.001 |
| Male, n                                        | 123                 | 95            |        |       |
| Duration of illness, y                         | 20.11 ± 12.45       | –             |        |       |
| Smokers, n (%)                                 | 76(23.7)            | 29(9.4)       | 22.985 | <0.001|
| BMI (kg/m²)                                    | 24.23 ± 4.40        | 23.94 ± 3.34  | 0.434  | 0.164 |
| Positive family history, n (%)                 | 76                  | 0             |        |       |
| Eye pressure left (mmHg)                       | 15.39 ± 3.32        | 15.39 ± 2.70  | 0.009  | 0.993 |
| Right (mmHg)                                   | 15.39 ± 3.33        | 15.24 ± 2.51  | 0.567  | 0.571 |
| Diopters(D) left eye                           | 3.07 ± 1.75         | 2.93 ± 1.14   | 0.255  | 0.800 |
| Right eye                                      | 3.14 ± 1.83         | 2.97 ± 1.32   | 0.265  | 0.793 |
| Olanzapine equivalent dose (mg/day)            | 2.58 ± 0.65         | –             | –      | –     |
| SBPᵃ (mmHg)                                    | 111.75 ± 9.16       | 110.85 ± 8.46 | 1.234  | 0.218 |
| DBPᵇ (mmHg)                                    | 71.28 ± 5.42        | 72.10 ± 5.98  | −1.752 | 0.083 |
| MAPᶜ (mmHg)                                    | 84.77 ± 6.05        | 85.02 ± 6.30  | −0.486 | 0.627 |
| ALTᵈ (U/L)                                     | 22.09 ± 20.28       | 20.16 ± 15.18 | 1.092  | 0.275 |
| ASTᵉ (U/L)                                     | 19.73 ± 8.46        | 19.31 ± 7.91  | 0.538  | 0.591 |
| Glucose (mmol/L)                               | 5.12 ± 1.16         | 5.43 ± 1.52   | −2.451 | 0.015 |
| Cholesterol (mmol/L)                           | 4.78 ± 0.84         | 3.99 ± 0.89   | −9.489 | <0.001|
| Triglyceride (mmol/L)                          | 1.58 ± 0.80         | 1.50 ± 1.25   | 0.829  | 0.408 |
| UAᶠ (mmol/L)                                   | 344.66 ± 98.16      | 321.70 ± 84.03| 2.515  | 0.012 |
| CNTF (pg/ml)ᵃ                                  | 1755.45 ± 375.73    | 1909.99 ± 368.08 | −3.347 | 0.001 |
| RBANSᵍ                                        |                     |               |        |       |
| Immediate memory                               | 91.22 ± 15.92       | 106.84 ± 10.51| −9.306 | <0.001|
| Visuospatial/Constructional                    | 94.78 ± 15.21       | 105.69 ± 14.91| −5.969 | <0.001|
| Language Index                                 | 92.91 ± 11.68       | 106.82 ± 9.55 | −10.597| <0.001|
| Attention Index                                | 104.12 ± 11.33      | 120.04 ± 16.56| −9.034 | <0.001|
| Delayed Memory                                 | 91.98 ± 14.28       | 111.14 ± 7.86 | −13.24 | <0.001|
| Total Scale                                    | 92.16 ± 15.03       | 117.64 ± 12.13| −15.322| <0.001|

Notes.
aSystolic blood pressure.
bDiastolic blood pressure.
cMean arterial pressure.
dAlanine aminotransferase.
eAspartate aminotransferase.
fUricacid.
gCNTF:Ciliary.
hNeurotrophic factor Repeatable Battery for the Assessment of Neuropsychology Status (RBANS).

of the subarea of RNFL, only the inferior and superior RNFL thickness of the right eye was associated with the course of illness. Similarly, cognitive impairments were also found significantly related to reduced thickness of RNFL. Thus, reduction in RNFL thickness might be a possible biomarker of schizophrenia.

Studies have reported reduction in thickness of the RNFL in patients with schizophrenia (Pan et al., 2018; Samani et al., 2018; Silverstein et al., 2018). Atrophy of the macula and the RNFL was also reported among the patients with schizophrenia spectrum disorder.
### Table 2 Comparison of retinal nerve fiber layer (RNFL) thickness and macular thickness in schizophrenia and normal control groups.

| Mean ± SD                  | Schizophrenia group | Control group | t  | P      | F   | P’   |
|---------------------------|---------------------|---------------|----|--------|-----|------|
| **Right RNFL**            |                     |               |    |        |     |      |
| Total thickness (µm)      | 88.18 ± 25.84       | 102.13 ± 14.32| −7.329 | <0.001 | 12.052 | 0.001 |
| Superior thickness (µm)   | 105.59 ± 36.68      | 120.13 ± 14.32| −4.521 | <0.001 | 11.177 | 0.001 |
| Inferior thickness (µm)   | 112.54 ± 37.91      | 130.17 ± 22.37| −6.169 | <0.001 | 10.369 | 0.001 |
| Disc area (mm²)           | 2.14 ± 1.10         | 2.34 ± 0.67   | −2.283 | 0.023  | 0.848  | 0.358 |
| Cup volume (mm³)          | 0.13 ± 0.13         | 0.11 ± 0.13   | 1.793  | 0.071  | 0.007  | 0.934 |
| **Left RNFL**             |                     |               |    |        |     |      |
| Total thickness (µm)      | 92.84 ± 13.54       | 103.71 ± 11.94| −8.637 | <0.001 | 33.130 | <0.001 |
| Superior thickness (µm)   | 114.80 ± 27.62      | 128.55 ± 22.51| −5.622 | <0.001 | 20.475 | <0.001 |
| Inferior thickness (µm)   | 117.49 ± 25.58      | 133.88 ± 18.68| −6.169 | <0.001 | 15.183 | <0.001 |
| Disc area (mm²)           | 2.09 ± 0.90         | 2.24 ± 0.57   | −2.088 | 0.037  | 0.086  | 0.770 |
| Cup volume (mm³)          | 0.14 ± 0.13         | 0.11 ± 0.13   | 2.533  | 0.012  | 1.815  | 0.179 |
| **Right macula (µm)**     |                     |               |    |        |     |      |
| Average thickness         | 253.12 ± 37.42      | 263.82 ± 41.93| −3.162 | 0.002  | 0.052  | 0.820 |
| Central thickness         | 217.65 ± 37.44      | 227.03 ± 23.87| −3.508 | <0.001 | 8.173  | 0.005 |
| Inner superior            | 277.85 ± 50.62      | 302.54 ± 16.22| −7.815 | <0.001 | 19.199 | <0.001 |
| Inner inferior            | 272.27 ± 49.74      | 293.47 ± 19.67| −6.652 | <0.001 | 9.396  | 0.002 |
| Inner nasal               | 283.03 ± 44.02      | 298.85 ± 30.97| −4.902 | <0.001 | 5.412  | 0.021 |
| Inner temporal            | 269.21 ± 53.20      | 287.27 ± 15.86| −5.476 | <0.001 | 2.570  | 0.110 |
| Outer ring superior       | 251.01 ± 44.88      | 267.60 ± 14.81| −5.906 | <0.001 | 9.336  | 0.002 |
| Outer inferior            | 238.61 ± 43.52      | 255.79 ± 15.11| −6.271 | <0.001 | 12.545 | <0.001 |
| Outer nasal               | 262.50 ± 49.28      | 283.07 ± 16.44| −6.660 | <0.001 | 8.138  | 0.0005 |
| Outer temporal            | 232.36 ± 45.22      | 248.99 ± 16.62| −5.801 | <0.001 | 3.628  | 0.058 |
| **Left macula (µm)**      |                     |               |    |        |     |      |
| Average thickness         | 254.67 ± 37.12      | 263.91 ± 36.37| −2.948 | 0.003  | 0.283  | 0.595 |
| Central thickness         | 218.04 ± 36.98      | 224.19 ± 21.71| −2.386 | 0.017  | 2.860  | 0.092 |
| Inner superior            | 281.47 ± 45.20      | 302.96 ± 17.16| −7.422 | <0.001 | 17.543 | <0.001 |
| Inner inferior            | 273.53 ± 44.44      | 292.06 ± 20.18| −6.332 | <0.001 | 16.942 | <0.001 |
| Inner nasal               | 284.27 ± 47.03      | 298.44 ± 26.10| −4.385 | <0.001 | 6.100  | 0.014 |
| Inner temporal            | 267.38 ± 40.36      | 282.70 ± 18.62| −5.749 | <0.001 | 11.939 | 0.001 |
| Outer superior            | 251.04 ± 40.32      | 267.11 ± 17.73| −6.088 | <0.001 | 15.278 | <0.001 |
| Outer inferior            | 242.68 ± 38.20      | 255.43 ± 18.16| −5.025 | <0.001 | 11.701 | 0.001 |
| Outer nasal               | 264.94 ± 43.81      | 279.0 ± 25.18 | −4.631 | <0.001 | 7.566  | 0.006 |
| Outer temporal            | 239.36 ± 36.31      | 247.96 ± 18.87| −3.501 | 0.001  | 4.442  | 0.036 |

**Notes.**

*P*, for *t*-test; *p’*, adjusted *p* for analysis of covariance after controlling for age, sex, olanzapine equivalent dose, and smoking.

(Schönfeldt-Lecuona et al., 2020). Findings of this study revealed decreased thickness of RNFL and macula in patients with schizophrenia which is in good agreement with results of the previously reported studies. Interestingly, reduction in RNFL thickness was found limited to the central macula of the right eye and the temporal quadrant macula of the left eye. Similarly, uneven reduction was also found in the two highly differentiated complex eyes in patients with schizophrenia spectrum disorder (Schönfeldt-Lecuona et al., 2020). The asymmetrical changes could be similar to the abnormal laterality (in terms of volume,
Table 3  Influence of CNTF and duration of illness on RNFL of schizophrenia patients (linear regression analysis).

|                       | CNTF | Duration of illness |
|-----------------------|------|---------------------|
|                       | Constant | β  | S.E. | F  | p  | Constant | β  | S.E. | F  | p  |
| Left RNFL             |         |    |      |    |    |         |    |      |    |    |
| Total thickness       | 199.64  | 0.012 | 0.006 | −2.220 | 0.032<sup>a</sup> | 199.64  | −0.657 | 0.192 | −3.416 | 0.002<sup>a</sup> |
| Inferior thickness    | 100.68  | −0.005 | 0.007 | −0.773 | 0.442 | 111.02  | 0.040 | 0.339 | 0.118 | 0.907 |
| Superior thickness    | 115.86  | −0.633 | 0.378 | −1.674 | 0.099 | 78.30   | 20.93 | 7.444 | 2.811 | 0.006 |
| Right RNFL            |         |    |      |    |    |         |    |      |    |    |
| Total thickness       | −47.63  | 0.018 | 0.008 | 2.327 | 0.023<sup>b</sup> | −47.63  | −0.720 | 0.296 | −2.433 | 0.017<sup>b</sup> |
| Inferior thickness    | −73.31  | 0.015 | 0.011 | 1.353 | 0.180 | −36.92  | −1.059 | 0.434 | −2.438 | 0.017<sup>b</sup> |
| Superior thickness    | −73.97  | −0.007 | 0.011 | 0.644 | 0.521 | 3.36    | −1.127 | 0.412 | −2.737 | 0.008 |

Notes.
*Linear regression model using each RNFL and macula alone as a dependent variable and CNTF (ciliary neurotrophic factor) and duration of illness as independent variables after controlling for age, sex, MAP, OED, smoker, uric acid, positive family history, glucose, and cholesterol levels.
<sup>a</sup>MAP as a significant covariate in the equation.
<sup>b</sup>Sex and MAP as significant covariates in the equation.
<sup>c</sup>Sex and uric acid as significant covariates in the equation.

Table 4  Influence of CNTF and RNFL on the cognitive function of schizophrenia patients.

|                   | CNTF | RNFL |
|-------------------|------|------|
|                   | Constant | β  | S.E. | F  | p  | Constant | β  | S.E. | F  | p  |
| Immediate memory  | 72.64  | −0.001 | 0.007 | −0.142 | 0.887 | 83.15    | 0.139 | 0.063 | 2.190 | 0.033 |
| Visuospatial/Constructional | 134.81 | 0.002 | 0.006 | 0.352 | 0.726 | 144.02   | 0.151 | 0.055 | 2.733 | 0.008<sup>a</sup> |
| Language Index    | 78.96  | 0.007 | 0.003 | 2.138 | 0.037 | 78.96    | 0.074 | 0.037 | 1.993 | 0.050 |
| Attention Index   | 110.88 | −0.003 | 0.005 | −0.577 | 0.566 | 104.77   | 0.030 | 0.045 | 0.672 | 0.504 |
| Delayed Memory    | 89.65  | 0.002 | 0.006 | 0.412 | 0.682 | 86.70    | 0.078 | 0.058 | 1.343 | 0.185 |
| Total             | 102.06 | 0.001 | 0.007 | 0.090 | 0.929 | 103.25   | 0.035 | 0.070 | 0.501 | 0.619 |

Notes.
*Linear regression model using the Index of RBANS as a dependent variable and CNTF and right RNFL as independent variables after controlling for age, sex, duration of illness, and smoking.
<sup>a</sup>Age and duration of illness as significant covariates in the equation.

Connectivity or function alterations found in the brains of patients with schizophrenia (Ribolsi et al., 2014). However, this is not in good agreement with another study reporting no significant atrophy in the RNFL, macula, or ganglion cell-inner plexiform layer thickness in schizophrenia patients (Silverstein et al., 2018), while the subgroup analyses showed significant atrophy in the “schizophrenia + comorbidity” group. The authors argued that the differences in structural retinal parameters reported in previous studies of OCT were possibly due to comorbidity with diabetes mellitus or hypertension. In case of our current study, abnormalities in the RNFL and the macula in patients with schizophrenia were clearly apparent even after controlling these confounding factors. Thus, it can be inferred that this reduction of RNFL may be the intrinsic characteristic change of schizophrenia patients. This in turn provides the base for considering reduction in RNFL thickness as possible cost-effective and non-invasive biomarker alone or in combination with other markers for early stage identification of schizophrenia in patients. Retinal structure abnormalities have been extensively reported as biomarkers for various other neurological conditions such as...
Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, multiple sclerosis and prion diseases (Yap et al., 2019). However, further follow-up research should be carried out in high-risk relatives to clarify if the retinal changes in schizophrenia occurred as a genetic endophenotype.

Significant correlations were found between the course of illness and the thickness of the RNFL, but not MT. This result is supported by a previous study reporting a similar significant correlation between RNFL thickness and the duration of illness (Lee et al., 2013). The atrophy of the RNFL has been proved to indicate a predominant neuron loss in the retina (Asanad et al., 2019). This association between RNFL and the course of illness may indicate the change of RNFL occurs at a certain stage or all times of the course. The changes in RNFL during schizophrenia give new insights about retina as a component of nervous system for non-invasive and low-cost diagnosis of the diseases. Thus, early detection of this abnormality may possibly help the clinicians in the early identification and effective intervention and management of schizophrenia.

The reduction of the RNFL was significantly correlated with the impairments of immediate memory and visuospatial function in our study. The confounding effects of schizophrenia severity and medication on the reduction of RNFL remain unclear (Kazakos & Karageorgiou, 2020). After having excluded the antipsychotics interference, we still detected the thinning of the RNFL and its relationship with cognitive impairments. It has been already proved that cognitive impairments in dementia are also related to atrophy of the RNFL (Chan et al., 2019). The neurodegenerative hypothesis is proven in the etiology of AD. Nevertheless, the thickness of the RNFL in older healthy people is less correlated with cognitive function. In contrast, the relationship between higher levels of cognitive function and a thicker RNFL in young healthy people may reflect a better development process of tissues in the entire forebrain (Van Koolwijk et al., 2009). The cognitive impairments appear at the beginning of schizophrenia, including loss of working memory. Thus, it can be assumed that the decrease in the RNFL thickness is related to cognitive impairment in the onset period, and the thinning of the RNFL structure may be one of the neurobiological biomarkers. As the course of schizophrenia continues, the reduction may become more obvious. It is suggested that early intervention in the reduction of the RNFL may improve the cognitive impairments of patients with schizophrenia.

CNTF is considered one of the members of the interleukin-6 cytokine family and a neurotrophic cytokine that plays a nutritional and regulatory role in retinal cells (Flachsbarth et al., 2018). Our study showed that CNTF deficiency may cause a reduction in the retinal nerve in patients with schizophrenia. CNTF is a common extracellular factor that prevents excessive production of opsins, photoreceptors of outer segments, and 11-cis-retinal to protect rods and cones from photodamage (Li et al., 2018). Intraocular administration of CNTF has been found to attenuate photoreceptor degeneration and preserve retinal functions in animal research models of inherited or induced retinal disease (Ghassemi et al., 2018). Studies have suggested that the CNTF plays an important role in the regeneration and repair of the optic nerve after injury (Leibinger et al., 2009). The CNTF is known to be the only neurotrophic factor that can effectively promote the regeneration of retinal optic ganglia, while other neurotrophic factors have been thought to promote
the regeneration of axons over long distances (Cui et al., 1999). Furthermore, the CNTF exhibited important protective effects against damage of hippocampal neurons (Liu et al., 2003). The alterations of the RNFL associated with decline in CNTF may represent one stage in the pathogenesis of schizophrenia, and the detailed changes and their relationship need further study. It will also be a new research direction in the future that intake of exogenous CNTF may retard the thinning of the RNFL and indirectly improve cognitive function in schizophrenia.

**Limitations**

There several limitations associated with this study. First, this was a cross-sectional study; therefore, confirm conclusion for the associations of serum CNTF, course of illness and RNFL thickness cannot be made. Second, enrolled patients had an average chronic illness course of 20 years. Thus, it is not clear whether RNFL abnormalities occurred before the onset of schizophrenia. Third, all of the patients had received antipsychotic treatment; this may have confounded our results. Future studies in this regard should be carried out in patients with no past or current history of using antipsychotics. Fourth, the thickness of the macula obtained with Topcon SD-OCT2002 was not a single-layer ganglion cell thickness; rather it was a cumulative ganglion cell complex owing to the automatic measurement limitation (Kazakos & Karageorgiou, 2020). A specific non-manual model for macular stratification may be a better method for further study (Schönfeldt-Lecuona et al., 2020). With the improvement in spatial resolution of OCT devices, cohort studies can be more reliable for investigating pathological changes in the retinas of schizophrenia patients.

**CONCLUSIONS**

By conducting a large-sample, single-center, cross-sectional study in chronic schizophrenia, our study suggests that RNFL thickness is associated with the course of illness in schizophrenia and the concentrations of serum CNTF. The reduction in RNFL thickness may be involved in the biological etiology of cognitive impairment among patients with schizophrenia and might also be a possible biomarker of schizophrenia. To authenticate retinal abnormalities as biomarkers for schizophrenia on mechanistic level, multi-centered studies employing multiple advanced techniques should be carried out in newly diagnosed schizophrenia patients.

**ACKNOWLEDGEMENTS**

We thank Lvzhen Huang and her team at Peking University and members of research team at our Integration of Traditional and Western Medicine Institute.
ADDITIONAL INFORMATION AND DECLARATIONS

Funding
This work was supported by the Beijing Municipal Science & Technology Commission No. Z181100001718115 and the Beijing Traditional Chinese Medicine Science and Technology project No. JJ2016-13. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures
The following grant information was disclosed by the authors:
Beijing Municipal Science & Technology Commission: Z181100001718115.
Beijing Traditional Chinese Medicine Science and Technology: JJ2016-13.

Competing Interests
The authors declare there are no competing interests.

Author Contributions
• Yanhong Liu conceived and designed the experiments, performed the experiments, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
• Lvzhen Huang conceived and designed the experiments, authored or reviewed drafts of the paper, and approved the final draft.
• Yongsheng Tong analyzed the data, prepared figures and/or tables, and approved the final draft.
• Jingxu Chen performed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.
• Dongfang Gao performed the experiments, authored or reviewed drafts of the paper, and approved the final draft.
• Fude Yang analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.

Ethics
The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):
Beijing Huilongguan Hospital of Peking University approved this study (2018-33).

Data Availability
The following information was supplied regarding data availability:
Raw data is available as Supplemental File.

Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.9279#supplemental-information.
REFERENCES

Adams SA, Nasrallah HA. 2018. Multiple retinal anomalies in schizophrenia. Schizophrenia Research 195:3–12 DOI 10.1016/j.schres.2017.07.018.

Asanad S, Ross-Cisneros FN, Nassisi M, Barron E, Karanjia R, Sadun AA. 2019. The retina in alzheimer’s disease: histomorphometric analysis of an ophthalmologic biomarker. Investigative Ophthalmology and Visual Science 60:1491–1500 DOI 10.1167/iovs.18-25966.

Ascaso FJ, Rodriguez-Jimenez R, Cabezón L, López-Antón R, Santabárbara J, Cámara CDela. 2015. Retinal nerve fiber layer and macular thickness in patients with schizophrenia: influence of recent illness episodes. Psychiatry Research 229:230–236 DOI 10.1016/j.psychres.2015.07.028.

Behbehani R, Al-Hassan AA, Al-Khars A, Sriraman D, Alroughani R. 2015. Retinal nerve fiber layer thickness and neurologic disability in relapsing-remitting multiple sclerosis. Journal of the Neurological Sciences 359:305–308 DOI 10.1016/j.jns.2015.11.017.

Bygrave AM, Jahans-Price T, Wolff AR, Sprengel R, Kullmann DM, Bannerman DM. 2019. Hippocampal-prefrontal coherence mediates working memory and selective attention at distinct frequency bands and provides a causal link between schizophrenia and its risk gene GRIA1. Translational Psychiatry 9:142–157 DOI 10.1038/s41398-019-0471-0.

Chan VTT, Sun Z, Tang S, Chen LJ, Wong A, Tham CC. 2019. Spectral-domain OCT measurements in alzheimer’s disease: a systematic review and meta-analysis. Ophthalmology 126:497–510 DOI 10.1016/j.ophtha.2018.08.009.

Chu EM, Kolappan M, Barnes TR, Joyce EM, Ron MA. 2012. A window into the brain: an in vivo study of the retina in schizophrenia using optical coherence tomography. Psychiatry Research 203:89–94 DOI 10.1016/j.psychresns.2011.08.011.

Cui Q, Lu Q, So KF, Yip HK. 1999. CNTF, not other trophic factors, promotes axonal regeneration of axotomized retinal ganglion cells in adult hamsters. Investigative Ophthalmology & Visual Science 40:760–766.

Di CP, Pergola G, Antonucci LA, Bonvino A, Mancini M, Quarto T. 2019. Multivariate patterns of gray matter volume in thalamic nuclei are associated with positive schizotypy in healthy individuals. Psychological Medicine Epub ahead of print Jul 30 2019 DOI 10.1017/S0033291719001430.

Flachsbarth K, Jankowiak W, Kruszewski K, Helbing S, Bartsch S, Bartsch U. 2018. Pronounced synergistic neuroprotective effect of GDNF and CNTF on axotomized retinal ganglion cells in the adult mouse. Experimental Eye Research 176:258–265 DOI 10.1016/j.exer.2018.09.006.

Gao ZT, Li YL, Guo SQ, Xia YH. 2019. Brain gray matter volume alterations and cognitive function in first-episode childhood-and adolescence-onset schizophrenia. Zhonghua Yi Xue Za Zhi 99:3581–3586.
Ghasemi M, Alizadeh E, Saei AK, Fallahi MB, Zarghami N. 2018. Ciliary neurotrophic factor (CNTF) delivery to retina: an overview of current research advancements. *Artificial Cells, Nanomedicine, and Biotechnology* 46:1694–1707.

Grimm CM, Aksamaz S, Schulz S, Teutsch J, Sicinski P, Liss B. 2018. Schizophrenia-related cognitive dysfunction in the Cyclin-D2 knockout mouse model of ventral hippocampal hyperactivity. *Translational Psychiatry* 8:212 DOI 10.1038/s41398-018-0268-6.

Hu SJ, You YA, Zhang Y. 2015. A study of retinal parameters measured by optical coherence tomography in patients with multiple sclerosis. *International Journal of Ophthalmology* 8:1211–1214.

Jonas JB, Wang N, Wang S, Wang YX, You QS, Yang D. 2014. Retinal vessel diameter and estimated cerebrospinal fluid pressure in arterial hypertension: the Beijing Eye Study. *American Journal of Hypertension* 27:1170–1178 DOI 10.1093/ajh/hpu037.

Kazakos CT, Karageorgiou V. 2020. Retinal changes in schizophrenia: a systematic review and meta-analysis based on individual participant data. *Schizophrenia Bulletin* 46:27–42.

Lavedan C, Volpi S, Polymeropoulos MH, Wolfgang CD. 2008. Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial. *Pharmacogenomics* 9:289–301 DOI 10.2217/14622416.9.3.289.

Lavoie J, Maziade M, Hébert M. 2014. The brain through the retina: the flash electroretinogram as a tool to investigate psychiatric disorders. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 48:129–134 DOI 10.1016/j.pnpbp.2013.09.020.

Lee WW, Tajunisah I, Sharmilla K, Peyman M, Subrayan V. 2013. Retinal nerve fiber layer structure abnormalities in schizophrenia and its relationship to disease state: evidence from optical coherence tomography. *Investigative Ophthalmology and Visual Science* 54:7785–7792 DOI 10.1167/iovs.13-12534.

Leibinger M, Müller A, Andreadaki A, Hauk TG, Kirsch M, Fischer D. 2009. Neuroprotective and axon growth-promoting effects following inflammatory stimulation on mature retinal ganglion cells in mice depend on ciliary neurotrophic factor and leukemia inhibitory factor. *Journal of Neuroscience* 29:14334–14341 DOI 10.1523/JNEUROSCI.2770-09.2009.

Li S, Sato K, Gordon WC, Sendtner M, Bazan NG, Jin M. 2018. Ciliary neurotrophic factor (CNTF) protects retinal cone and rod photoreceptors by suppressing excessive formation of the visual pigments. *Journal of Biological Chemistry* 293:15256–15268 DOI 10.1074/jbc.RA118.004008.

Liu F, Yan J, Jiang ZL, Wang XQ, Bao X, Lu CL. 2003. Effects of CNTF on the nuclear translocation of PKC following NMDA administration in primary hippocampal neurons. *Zhongguo Ying Yong Sheng Li Xue Za Zhi* 19:145–148.

Man L, Lv X, Du XD, Yin G, Zhu X, Zhang Y. 2018. Cognitive impairments and low BDNF serum levels in first-episode drug-naive patients with schizophrenia. *Psychiatry Research* 263:1–6 DOI 10.1016/j.psychres.2018.02.034.
Meier MH, Gillespie NA, Hansell NK, Hewitt AW, Hickie IB, Lu Y. 2015. Retinal microvessels reflect familial vulnerability to psychotic symptoms: a comparison of twins discordant for psychotic symptoms and controls. *Schizophrenia Research* 164:47–52 DOI 10.1016/j.schres.2015.01.045.

Moschos MM, Markopoulos I, Chatziralli I, Rouvas A, Papageorgiou SG, Ladas I. 2012. Structural and functional impairment of the retina and optic nerve in Alzheimer’s disease. *Current Alzheimer Research* 9:782–788 DOI 10.2174/156720512802455340.

Neugebauer K, Hammans C, Wensing T, Kumar V, Grodd W, Mevissen L. 2019. Nerve growth factor serum levels are associated with regional gray matter volume differences in schizophrenia patients. *Frontiers in Psychiatry* 10:275.

Nunes PV, Nascimento CF, Kim HK, Andreazza AC, Brentani HP, Suemoto CK. 2018. Low brain-derived neurotrophic factor levels in post-mortem brains of older adults with depression and dementia in a large clinicopathological sample. *Journal of Affective Disorders* 241:176–181 DOI 10.1016/j.jad.2018.08.025.

Pan J, Zhou Y, Xiang Y, Yu J. 2018. Retinal nerve fiber layer thickness changes in Schizophrenia: a meta-analysis of case-control studies. *Psychiatry Research* 270:786–791 DOI 10.1016/j.psychres.2018.10.075.

Randolph C, Tierney MC, Mohr E, Chase TN. 1998. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. *Journal of Clinical and Experimental Neuropsychology* 20:310–319 DOI 10.1076/jcen.20.3.310.823.

Ribotsi M, Daskalakis ZJ, Siracusano A, Koch G. 2014. Abnormal asymmetry of brain connectivity in schizophrenia. *Frontiers in Human Neuroscience* 8:1010 DOI 10.3389/fnhum.2014.01010.

Samani NN, Proudlock FA, Siram V, Suraweera C, Hutchinson C, Nelson CP. 2018. Retinal layer abnormalities as biomarkers of schizophrenia. *Schizophrenia Bulletin* 44:876–885 DOI 10.1093/schbul/sbx130.

Satue M, Seral M, Otin S, Alarcia R, Herrero R, Bambo MP. 2014. Retinal thinning and correlation with functional disability in patients with Parkinson’s disease. *British Journal of Ophthalmology* 98:350–355 DOI 10.1136/bjophthalmol-2013-304152.

Schönfeldt-Lecuona C, Kregel T, Schmidt A, Kassubek J, Dreyhaupt J, Freudenmann RW. 2020. Retinal single-layer analysis with optical coherence tomography (OCT) in schizophrenia spectrum disorder. *Schizophrenia Research* 219:5–12.

Semkova I, Häberlein C, Kriegstein J. 1999. Ciliary neurotrophic factor protects hippocampal neurons from excitotoxic damage. *Neurochemistry International* 35:1–10 DOI 10.1016/S0197-0186(99)00021-2.

Shiba T, Takahashi M, Matsumoto T, Hori Y. 2017. Relationship between metabolic syndrome and ocular microcirculation shown by laser speckle flowgraphy in a hospital setting devoted to sleep apnea syndrome diagnostics. *Journal of Diabetes Research* 2017:3141678.

Silverstein SM, Paterno D, Cherneski L, Green S. 2018. Optical coherence tomography indices of structural retinal pathology in schizophrenia. *Psychological Medicine* 48:2023–2033 DOI 10.1017/S0033291717003555.
Silverstein SM, Rosen R. 2015. Schizophrenia and the eye. Schizophrenia Research: Cognition 2:46–55 DOI 10.1016/j.scog.2015.03.004.

Van Koolwijk LM, Despriet DD, Van Duijn CM, Oostra BA, Van Swieten JC, De Koning I. 2009. Association of cognitive functioning with retinal nerve fiber layer thickness. Investigative Ophthalmology and Visual Science 50:4576–4580 DOI 10.1167/iovs.08-3181.

Wang YY, Wang S, Zheng W, Zhong BL, Ng CH, Ungvari GS. 2019. Cognitive functions in smoking and non-smoking patients with schizophrenia: a systematic review and meta-analysis of comparative studies. Psychiatry Research 272:155–163 DOI 10.1016/j.psychres.2018.12.064.

Wässle H. 2004. Parallel processing in the mammalian retina. Nature Reviews Neuroscience 5:747–757 DOI 10.1038/nrn1497.

Yap TE, Balendra SI, Almonte MT, Cordeiro MF. 2019. Retinal correlates of neurological disorders 2019. Therapeutic Advances in Chronic Disease 10:204062319882205.

Zhang C, Ni P, Liu Y, Tian Y, Wei J, Xiang B. 2019. GABAergic abnormalities associated with sensorimotor cortico-striatal community structural deficits in ErbB4 knockout mice and first-episode treatment-Naïve patients with schizophrenia. Neuroscience Bulletin 36(2):97–109.